


Important Updates from the CDC on COVID-19 Therapeutics for Treatment and Prevention | AMDA | The Society for Post-Acute and Long-Term Care Medicine

 $\frac{https://paltc.org/?q=content/important-updates-cdc-covid-19-therapeutics-treatment-and-prevention\#overlay-context=content/important-updates-cdc-covid-19-therapeutics-treatment-and-prevention\%3Fq\%3Dcontent/important-updates-cdc-covid-19-therapeutics-treatment-and-prevention$

Distributed via the CDC Health Alert Network December 20, 2022, 5:45 PM ET CDCHAN-00483



The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Update to supplement the CDC HAN Health Advisories issued on April 25, 2022 and May 24, 2022 to emphasize to healthcare providers, public health departments, and the public that the majority of Omicron sublineages circulating in the United States have reduced susceptibility to the monoclonal antibody, bebtelovimab and the monoclonal antibody combination, cilgavimab and tixagevimab (EvusheldTM).



Important Updates from the CDC on COVID-19 Therapeutics for Treatment and Prevention \mid AMDA \mid The Society for Post-Acute and Long-Term Care Medicine

Antiviral therapeutics for the treatment of COVID-19, ritonavir-boosted nirmatrelvir (PaxlovidTM), remdesivir (Veklury®), and molnupiravir (LagevrioTM), retain activity against currently circulating Omicron sublineages. These medications can prevent severe disease, hospitalization, and death and are widely available but have been underused.